Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Patients With Severe Systemic Sclerosis.

Trial Profile

Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Patients With Severe Systemic Sclerosis.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Mar 2017

At a glance

  • Drugs Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Antithymocyte globulin; Mycophenolate mofetil; Mycophenolate mofetil; Tacrolimus
  • Indications Allotransplant rejection; Graft-versus-host disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Mar 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Mar 2018.
    • 16 Apr 2012 Planned end date changed from 1 Dec 2014 to 1 Sep 2017 as reported by ClinicalTrials.gov.
    • 20 Jan 2012 Additional lead trial investigator identified as reported by University of Washington Health Sciences.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top